New York, February 16, 2026, 11:40 (EST) — The market is shut.
Eli Lilly and Company turned in upbeat topline data from a pivotal trial of its cancer therapy Retevmo, teeing up a new challenge for the stock as U.S. markets get back to action Tuesday after the holiday.
This update signals Retevmo could see use beyond just advanced disease, potentially shifting the drug into earlier lines and keeping patients on treatment longer. For Lilly, it’s more evidence their growth narrative extends past obesity drugs alone.
Awkward timing: with U.S. stock exchanges closed Monday for Presidents Day, any market response to the trial news will have to wait until the next trading session.
Lilly stock hovered at $1,040 Friday afternoon, tacking on $2.18, or 0.2%, from its previous finish. Shares moved within a range of $1,033.32 to $1,063.68 during the day.
Lilly reported that its Phase 3 LIBRETTO-432 study showed Retevmo (selpercatinib) outperformed placebo on event-free survival as an adjuvant treatment in early-stage RET fusion-positive non-small cell lung cancer. Adjuvant therapy, given after surgery or radiation, aims to keep cancer from coming back. “Cancer medicines can deliver their greatest impact when administered early,” said Jacob Van Naarden, president of Lilly Oncology. The drugmaker noted that while overall survival results favored Retevmo, those numbers aren’t mature enough for conclusions yet. Full results are slated for a future medical conference. PR Newswire
Event-free survival remains a go-to benchmark in cancer trials. Simply put, it measures the time patients make it before their cancer returns, gets worse, or leads to death.
There’s the commercial ceiling to consider, too. RET fusions make up only a tiny segment of lung cancer cases, and the adjuvant market is notorious for tough debates over who really stands to gain and just how much benefit is there.
Lilly flagged CFO Lucas Montarce’s upcoming slot at TD Cowen’s health care conference—he’s scheduled for 3:10 p.m. Eastern on March 2. Investors tend to use this forum to dig into pricing, supply, and what’s coming down the pipeline.
Outside of cancer, Lilly’s push into metabolic disease is drawing close attention from traders. According to Reuters, the company has stockpiled large quantities of orforglipron, its experimental oral weight-loss drug, as it waits for an FDA decision in April. The stakes are rising, with Novo Nordisk also ramping up efforts with its competing treatments.
But those headline results don’t always translate into wins. Investors will be combing through hazard ratios, the side-effect landscape, and subgroup consistency before assigning value to any future sales potential.
Here’s what’s next: Tuesday’s open. After the long weekend, traders are watching for the Retevmo readout to see if it brings in fresh buyers. The next scheduled management commentary isn’t until March 2.
